According to the company, the new research demonstrates the ingredient’s neuroprotective qualities and potential to enhance cognitive function, and support healthy brain aging.
Kyowa Hakko USA ( New York) has announced in a press release that the company will be showcasing new research at SupplySide West 2024 taking place in Las Vegas, NV between October 30-31. The research provides further validation of its recently patented citicoline ingredient called Cognizin. According to the company, the new research demonstrates the ingredient’s neuroprotective qualities and potential to enhance cognitive function, and support healthy brain aging. The research was unveiled this past summer at the American Society for Nutrition (ASN) Nutrition2024 Conference.
“We are ecstatic to bring new research supporting the efficacy of Cognizin to center stage at SupplySide West,” said Katie Emerson, Kyowa Hakko’s senior manager, scientific affairs, in a press release. “We now understand at the genetic level how citicoline delivers its benefits and could have greater implications for long-term brain health.”
Show attendees will be able to sample Cognizin in a limited edition energy drink designed exclusively at the show, called XPO NRG.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
2 Commerce Drive
Cranbury, NJ 08512